Comparing and Explaining Differences in the Magnitude, Content, and Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D Multiattribute Utility Instruments

Richardson, Jeffrey Ralph James; Khan, Mumtaz Ahmad; Iezzi, Angelo; Maxwell, A S

doi:10.1177/0272989x14543107

Cited by 127 publications

(111 citation statements)

References 22 publications

(30 reference statements)

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…There are four different versions of the ASCOT instrument [59], to be used in different circumstances, and three different ICECAP measures for different patient types (see above), plus the O-CAP variations and instruments developed specifically to assess quality of life in Malawi and chronic pain. Not unlike the multiple MAUIs [37], there is no gold standard; while they all purport to measure capability they will be measuring different aspects of it. NICE technology appraisals avoid this given the stated preference for the use of the EQ-5D, at least in terms of adult conditions; there is less specificity around measuring HR-QoL for children, and the public health and social care guidance are even less prescriptive.…”

Section: Outstanding Issuesmentioning

confidence: 99%

See 1 more Smart Citation

Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach

Lorgelly

2015

PharmacoEconomics

View full text Add to dashboard Cite

The last decade has seen a renewed interest in Sen's capability approach; health economists have been instrumental in leading much of this work. One particular stream of research is the application of the approach to outcome measurement. To date, there have been a dozen attempts (some combined) to operationalise the approach, and produce an outcome measure that offers a broader evaluative space than health-related quality-of-life measures. Applications have so far been confined to public health, physical, mental health and social care interventions, but the capability approach could be of benefit to evaluations of pharmacotherapies and other technologies. This paper provides an introduction to the capability approach, reviews the measures that are available for use in an economic evaluation, including their current applications, and then concludes with a discussion of a number of issues that require further consideration before the approach is adopted more widely to inform resource allocation decisions.

show abstract

Section: Outstanding Issuesmentioning

confidence: 99%

“…Note that one of the most detailed comparison studies, the multiinstrument comparison (MIC) study includes ICECAP-A and six other MAUIs (EQ-5D-5L, AQoL-8D, HUI3, 15D, QWB and the SF-6D)[37].…”

mentioning

confidence: 99%

Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach

Lorgelly

2015

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…18 Broadly speaking, direct methods are considered theoretically superior but more administratively burdensome to implement than indirect methods; indirect methods are more convenient and can easily be integrated into clinical trials, but have practical limitations in their sensitivity to effects. 19,20 Both methods produce theoretically equivalent results, although in practice differences across methods have been observed. 21 …”

Section: Methodsmentioning

confidence: 99%

Measuring benefits of opioid misuse treatment for economic evaluation: health‐related quality of life of opioid‐dependent individuals and their spouses as assessed by a sample of the US population

Wittenberg¹,

Bray

Aden

et al. 2015

Addiction

View full text Add to dashboard Cite

Aims To understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. Design Cross-sectional internet survey of a US-population-representative respondent panel conducted December 2013-January 2014. Setting USA. Participants 2,054 randomly-selected adults; 51% male (before weighting). Measurements Mean (95% CI) and median health “utility” for 6 opioid misuse and treatment outcomes: active injection misuse; active prescription misuse; methadone maintenance therapy at initiation, and when stabilized in treatment; and buprenorphine therapy at initiation, and when stabilized. Utility is a numerical representation of health-related quality of life used in economic evaluations to “adjust” estimated survival to include peoples' preferences for health states. Utilities are determined by surveying the general population to estimate the value they assign to particular health states—on a scale where 0=the value of being dead, and 1.0=the value of being in perfect health. Spouse spillover utility is assigned to a spouse of an individual who is in a particular health state. Findings Mean individual utility ranged from 0.574 (95%CI: 0.538, 0.611) for active injection opioid misuse to 0.766 for stabilized buprenorphine therapy (95%CI: 0.738, 0.795), with other states in between. Female respondents assigned higher utility to the active prescription misuse and buprenorphine therapy at initiation states than did males (p<0.05); all other states did not differ by respondent gender. Mean spousal utilities were significantly lower than 1.0 but mostly higher than individual utility, and were similar between male and female respondents. Conclusions In the opinion of the US public, injection opioid misuse results in worse health-related quality of life than prescription misuse, and methadone therapy results in worse health-related quality of life than buprenorphine therapy. Spouses are negatively affected by their partner's opioid misuse and early treatment.

show abstract

“…A further cited limitation is the discrepancies in utility values when measured with different preference-based instruments [20][21][22][23][24]. Richardson et al [25] compared the utilities in patients from seven disease areas and compared them with values from healthy members from the public using six instruments, including the EQ-5D, SF-6D, HUI3, 15D, Quality of Well-Being, and Assessment of Quality of Life (AQoL). The results revealed that the magnitude of utility difference varied with the choice of instrument by more than 50% for every disease group.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review

Xin

McIntosh

2016

Qual Life Res

View full text Add to dashboard Cite

ResultsTwenty-three of 2,758 studies were included, of which the majority evidence was for EQ-5D. Overall, good evidence of discriminant validity was demonstrated in the Health Utility Index (HUI)-3, EQ-5D-5L, EQ-5D-3L, 15D, HUI-2 and Disability and Distress Index (DDI). Nevertheless, HUI-2 and EQ-5D-3Lwere shown to be less sensitive among patients with mild Parkinson's. Moderate to strong correlations were shown between the PbQoL measures (EQ-5D-3L, EQ-5D-5L, 15D, DDI, and HUI-II) andParkinson's-specific measures. Twelve studies provided evidence for the assessment of responsiveness of EQ-5D-3L and one study for 15D, among which six studies reached inconsistent results between EQ-5D-3L and the Parkinson's-specific measures in measuring the change overtime. ConclusionsThe construct validity of the PbQoL measures was generally good, but there are concerns regarding their responsiveness to change. In Parkinson's, the inclusion of a Parkinson's-specific QoL measure or a generic but broader scoped mental and well-being focused measure to incorporate aspects not included in the common PbQoL measures is recommended. Keywords

show abstract

Comparing and Explaining Differences in the Magnitude, Content, and Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D Multiattribute Utility Instruments

Cited by 127 publications

References 22 publications

Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach

Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach

Measuring benefits of opioid misuse treatment for economic evaluation: health‐related quality of life of opioid‐dependent individuals and their spouses as assessed by a sample of the US population

Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review

Contact Info

Product

Resources

About